Technical and Economical Evaluation of Downstream Processing Options for Monoclonal Antibody (Mab) Production - Updated downstream processes can pave the way for increased productivity, now and in the


Technical and Economical Evaluation of Downstream Processing Options for Monoclonal Antibody (Mab) Production
Updated downstream processes can pave the way for increased productivity, now and in the future.

BioPharm International

Thus, efforts to improve downstream technologies should focus more on the ability of the downstream process to handle an ever increasing mass of drug product rather than on the raw material or step costs. We believe that this interpretation will remain relevant until there is a paradigm shift to entirely different unit operations that offer similar overall purification performance, safety, and robustness without constraints in mass and volume handling and at a cost of ownership below current costs for membranes and resins.

Emerging Reference Process for MAbs

Figure 6. Schematic overview of consensus process design (left), resins for the generation 2 process (middle), and other options that have been tested by the industry (right).
Initial data about the design of a reference process were recently published and are used for research purposes of GE Healthcare Life Sciences (Figure 6).2,4 This is a second generation process using similar purification principles and step sequences to the current, most widely used platform process used to manufacture today's MAbs as described in the literature and at recent scientific conferences. The current most popular process may use resin and membrane products from different suppliers, but almost all are from the same generation as Sepharose Fast Flow. Consequently, for the most part, the latest generation of downstream purification technology is not being used.

The purpose of the development project is to address challenges such as the increase in upstream productivity of monoclonal antibodies in an integrated fashion (not solely in selected step improvements), and to remove downstream process bottlenecks now and in the near future. Notwithstanding other development projects and their possible outcome, it is our goal that the resin technology selected for this process will remain relevant for most processes developed in the next 5–10 years and be able to remain in full scale production for the next two decades with no need to alter the fundamental design. This goal coincides with the need to avoid major process changes that delay development and increase regulatory costs in the industry. Improvements offered by the new reference process compared with current popular practices can be described by two categories: process robustness, and productivity and costs.

Process Robustness

Figure 7. The stability of a novel Protein A resin ("MAbSelect SuRe," GE Healthcare) following several hundred clean-in-place cycles with 0.1 M NaOH..
In any downstream process sequence, the capture step dominates robustness in many ways. Capture transfers the drug product into a stable environment, concentrates the dilute feed ~10 fold, and ideally removes most impurities that could compromise the stability of the drug throughout the remainder of the process time. It also minimizes the level of impurities to a low level handled reproducibly by subsequent polishing steps, independent of feed stream quality variations. The robustness period can be extended to include robust performance between various development projects, covering a wide range of monoclonal antibodies (i.e., a"platform").

blog comments powered by Disqus



AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International,
Click here